MYC alterations in hematological cancers differ from the ones observed in solid tumors, e.g., the former predominantly present MYC translocations and point mutations, while the latter are mostly characterized by MYC amplifications [24]. Here, MYC is linked to hematopoietic and lymphoid cell neoplasm.